StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Allogene Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Allogene Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$102.20M. For fiscal 2025 it was -$149.25M. The highest annual figure on record is -$44.65M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$149.25M–
FY2024Dec 31, 2024-$200.30M–
FY2023Dec 31, 2023-$237.73M–
FY2022Dec 31, 2022-$220.52M–
FY2021Dec 31, 2021-$184.81M–
FY2020Dec 31, 2020-$115.09M–
FY2019Dec 31, 2019-$137.35M–
FY2018Dec 31, 2018-$44.65M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.00M–
Q1 FY2026Mar 31, 2026-$12.91M–
Q4 FY2025Dec 31, 2025-$27.60M–
Q3 FY2025Sep 30, 2025-$29.69M–
Q2 FY2025Jun 30, 2025-$39.03M–
Q1 FY2025Mar 31, 2025-$52.93M–
Q4 FY2024Dec 31, 2024-$36.70M–
Q3 FY2024Sep 30, 2024-$44.12M–
Q2 FY2024Jun 30, 2024-$63.59M–
Q1 FY2024Mar 31, 2024-$55.90M–
Q4 FY2023Dec 31, 2023-$53.71M–
Q3 FY2023Sep 30, 2023-$55.53M–
Q2 FY2023Jun 30, 2023-$61.86M–
Q1 FY2023Mar 31, 2023-$66.64M–
Q4 FY2022Dec 31, 2022-$62.10M–
Q3 FY2022Sep 30, 2022-$47.66M–
Q2 FY2022Jun 30, 2022-$42.53M–
Q1 FY2022Mar 31, 2022-$68.24M–
Q4 FY2021Dec 31, 2021-$45.44M–
Q3 FY2021Sep 30, 2021-$48.88M–
Q2 FY2021Jun 30, 2021-$41.17M–
Q1 FY2021Mar 31, 2021-$49.33M–
Q4 FY2020Dec 31, 2020-$9.98M–
Q3 FY2020Sep 30, 2020-$37.59M–
Q2 FY2020Jun 30, 2020-$26.72M–
Q1 FY2020Mar 31, 2020-$40.81M–
Q4 FY2019Dec 31, 2019-$50.27M–
Q3 FY2019Sep 30, 2019-$31.94M–
Q2 FY2019Jun 30, 2019-$24.89M–
Q1 FY2019Mar 31, 2019-$30.26M-605220.0%
Q4 FY2018Dec 31, 2018-$21.48M–
Q3 FY2018Sep 30, 2018-$17.13M–
Q2 FY2018Jun 30, 2018-$6.05M–
Q1 FY2018Mar 31, 2018$5.00K–

More Allogene Therapeutics figures

See a number that looks wrong?